Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
Catherine Marshall discusses fatigue, functional decline, and treatment burden in metastatic castrate-sensitive prostate cancer. Dr. Marshall frames fatigue not as a subjective co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results